June 20, June 20, is nearing the end of June, meaning more than half of 2017. As of June 19, more than 60 companies in a-share listed companies have reported earnings for the first half of the year, with 44 of them, accounting for nearly 67%. Three of the six companies expected to make a net profit of more than 500 million yuan are new faces, and will they be able to squeeze in the $1 billion this year? Why was the company's net profit growth of more than 400% in the first half of 2017? Why did the loss of the pharmaceutical industry "stop"? The mystery is now revealed.
Three "new faces", who can squeeze into the "billion legion"
Has released the first half of the a-share listed companies of earnings forecast, faith litai last year net profit of more than 1 billion yuan, Shanghai and alex's new and become, the three drug firms in the first half of 2017 net profit is expected to exceed 500 million yuan, the overall performance of the rising momentum.
Its annual net profit for 2016 was $780m. Net profit in the first half of 2017 is expected to be around 490 million yuan to about 550 million yuan, with a range of 20 to 35 percent. The company reported in the first quarter that the main reason for the increase was the increase in sales of blood products. In addition, this year on April 7, a wholly owned subsidiary of chongqing made by hualan bio-engineering engineering co., LTD., received the CFDA people immunoglobulin production, approval documents issued by the specification of 150 mg/bottle of 1.5 ml (10%) and 300 mg/bottle of 3 ml (10%), drug approval number for S20170001 and approved by the S20170002 approved by the state and is expected to help the company to further improve the overall performance.
In 2016, the company's net profit was 591 million yuan. Net profit for the first half of 2017 is expected to be about 450 million yuan to 550 million yuan, with a change of 105% to 155%. The company reported in the first quarter that the main reason for the surge in net profit was the growth in revenue and the execution of new bad loans.
Its net profit for 2016 was 705 million yuan. Net profit for the first half of 2017 is expected to be about rmb420m to $530 million, with a range of 15% to 45%. The company reported in the first quarter that the price of a series of products such as vitamin B5, the main reason for the increase, had increased significantly in the same period last year. The company is the world's largest producer and supplier of vitamin B5 and B5, which will continue to benefit as the product market moves forward.
In the first half of the year, net profit growth was expected to exceed 100%
The company reported the biggest increase in sales in the first half of 2017, with 435.63 percent to 484.33 percent, while net profit was estimated at 110 million yuan to 120 million yuan. There are three main reasons for the growth in the first half of 2017: the steady increase in sales of prescription drugs; Second, the increase in sales of OTC medicines; Third, the sales of ginseng products are expected to increase greatly.
However, the company also noted that there are still uncertainties about the sale of ginseng products in the semi-annual period of 2017. Once the product is expected to fail, it will have a major impact on the company's semi-annual performance in 2017. The company's ginseng products are divided into crude processing products and deep processing products, including white ginseng, red ginseng, raw ginseng and other products. Deep processing of products include ginseng ears beverage fermented beverages, ginseng fruits and vegetables, fresh ginseng honey slice, jade beauty red ginseng gelatin cakes, moulded red ginseng, ginseng stem leaf extract, ginseng extract and red ginseng red jujube solid drink and so on, the company has four series of ginseng food production license, confectionery products including beverages, alternative products, candied fruit, tea and tea, etc. According to the 2016 annual report, the gross margin of the company's ginseng series is 76.37%.
Yangtze river rt mart, according to the announcement on May 27, in view of the company and pay cash purchase of assets through issuing shares and raising matching funds and the related transactions of the material assets reorganization has been completed, the new shares have been listed on November 18, 2016, at present, the company main business covers the original elevator guide rail industry and new medicine manufacturing business, the company changed its name to "Yangtze river embellish hair medicine co., LTD.". In the first half of the company expects net profit of 140 million yuan to 170 million yuan, increase between 105.27% ~ 105.27%, according to quarter report, due to the company under the same control enterprise merger in 2016, traces the adjustment the financial statements, due to the increase in consolidation scope, at the same time the company profit ability is greatly increased.
The three companies are expected to lose money in the first half of the year
Nine Ann medical net profit fluctuated in recent three years, 2014 net income of 10.1975 million yuan, the loss of 151 million yuan in 2015, 2016 net income of 14.5 million yuan, 2017 expected losses during the first half of 40 million ~ 60 million yuan. According to the company in the first quarter to show results the loss of the reason is that the company continues to accelerate the "wearable device and intelligent hardware for entry into the mobile medical and health field of big data, and build healthy ecosystem around user" strategy, take the initiative to choose by traditional a generation of labor enterprise transformation, in the direction of health management based on mobile Internet marketing investment and management costs in the short term (including r&d) into a larger, prophase investment into a corresponding profits still needs a period of time.
In the first quarter of last year, it reported a loss of 388 million yuan for the whole of 2016, and a projected loss of 14 million to 16 million yuan in the first half of 2017. Double as pharmaceutical industry, said the semi-annual sales situation better, compared to the losses narrowed somewhat, but still have not reached the management forecast, the main reason is that the pharmaceutical industry policy and bidding, market development cost is increased, product sales increasing gross margin to cover costs.
Watson had a net profit of $841 million in 2015, while net profit rebounded to 746 million yuan in 2016, and is expected to be a loss in the first half of 2017. The company said, according to the research and development of project strategic planning, in the first half of 2017 the company will focus on the advantages of resources, actively promote the price of 13 pneumococcal polysaccharide conjugate vaccine, recombinant human papilloma virus bivalent vaccine type (16/18) (yeast), single key products such as drug resistance of clinical research and industrialization of project construction. The research and development of the company's rich bio-pharmaceutical projects is characterized by high input and long period, which may result in a loss of net profit in the first half of the year.
Source: the company's performance forecast |
